Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression, Depressive Disorder, Depress...
Phase NA
Enrollment 8
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression. Participants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: OHDC-DC — 90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period

Primary Outcomes

  • Change in Personal Health Questionnaire Depression Scale score (Baseline to one month post-intervention (approximately 12 weeks))
  • Change in Generalized Anxiety Disorder 7-item (GAD-7) score (Baseline to one month post-intervention (approximately 12 weeks))
  • Change in Quick Inventory of Depressive Symptomatology (QIDS) (Baseline to one month post-intervention (approximately 12 weeks))
  • Satisfaction with intervention (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 8 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Principal Investigators:
  • Earlise Ward, PhD (PRINCIPAL_INVESTIGATOR) - University of Wisconsin, Madison
Contact Information
Study Contact:
Shari Barlow
608-265-4348
shari.barlow@fammed.wisc.edu
Shari Barlow
608-265-4348
shari.barlow@fammed.wisc.edu
University of Wisconsin
Earlise Ward, PhD
University of Wisconsin
Interventions
  • Behavioral: OHDC-DC — 90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
Study Locations (1 sites)
University of Wisconsin, Madison, Wisconsin 53705 United States
Eligibility Criteria
Inclusion Criteria: * African-American * Age 18 and older * Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9) * Own a mobile phone Exclusion Criteria: * Individuals who are currently receiving psychotherapy * Individuals who are presently experiencing suicidal ideation * Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study * Participants scoring 25 or higher on the PHQ-9 will be screened out
Conditions Advanced Breast Cancer, Treatment, HR Lo...
Phase PHASE2
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Experimental: chemotheyapy — nab-paclitaxel 130mg/m2,day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2,day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2,day 1 and day 8 + Capecitabine 2000mg/m2,from day1 to DAY 14
  • Drug: Active Comparator: endocrine therapy — palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days

Primary Outcomes

  • ORR by investigator using RECIST Guideline (Version 1.1) (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-01-01
Completion: 2026-12-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Cancer Hospital
Contact Information
Study Contact:
Min Yan, M.D.
+8615713857388
ym200678@126.com
Min Yan, Doctor
+86 15713857388
ym200678@126.com
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University
Min Yan, Doctor
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University
Interventions
  • Drug: Experimental: chemotheyapy — nab-paclitaxel 130mg/m2,day 1 and day 8 + Capecitabine 2000mg/m2, followed by nab-paclitaxel 130mg/m2,day 1 and day 8 or Capecitabine from day1 to DAY 14 Vinorelbine 25mg/m2,day 1 and day 8 + Capecitabine 2000mg/m2,from day1 to DAY 14
  • Drug: Active Comparator: endocrine therapy — palbociclib 125mg per day for 21days Dalpiciclib 150mg per day for 21days Letrozole 2.5mg per day Anastrozole 1mg per day fulvestrant 500mg per 28 days
Study Locations (1 sites)
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: 1. age ≥18 years old; Invasive breast cancer with metastatic disease confirmed by histological or cytological examination; Patients without pathologically or cytologically confirmed metastatic disease should have clear evidence of metastasis by physical examination or radiological studies; 2. The most recent pathological report of biopsy confirmed HR low expression and HER2 negative. 1. HR low expression was defined as 1-50% ER expression by immunohistochemistry (IHC); Or ER\<1% and PR≥1%; Patients with ER expression of 1-10% or ER-/ PR-positive patients were eligible for inclusion after careful evaluation by the investigator, and those with a small tumor burden and candidates for endocrine therapy were eligible. 2. HER2-negative definition: IHC 0 or 1+; If the IHC was 2+, it was confirmed negative by fluorescence in situ hybridization (FISH). 3. at least one measurable lesion; 4. No previous salvage chemotherapy for metastatic disease was required, and first-line endocrine therapy was allowed; 5. no previous CDK4/6 inhibitor; For adjuvant CDK4/6i treatment, recurrence and metastasis were required more than 1 year after drug withdrawal. 6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, life expectancy is more than 12 weeks; 7. Adequate function of major organs. 8. All adverse events recovered to grade 1 or less before enrollment (NCI CTCAE version 5.0); 9. patients without major organ dysfunction and heart disease; 10. Women and men of childbearing potential must agree to use appropriate contraception before and during study participation. Exclusion Criteria: 1. symptomatic, uncontrolled brain or leptomeningeal metastases; Patients who had received previous systemic radical treatment for brain metastases (radiotherapy or surgery), if stable disease had been maintained for at least 1 month as confirmed by imaging, and if systemic hormone therapy (dose 10mg/ day prednisone or other effective hormones) for more than 2 weeks without clinical symptoms. 2. patients received radiotherapy, chemotherapy, major surgery, targeted therapy or immunotherapy within 2 weeks before enrollment; Patients received endocrine therapy within 1 week before enrollment. Chemotherapy with nitrosourea or mitomycin was administered within 6 weeks before enrollment. 3. participated in other clinical trials of new drugs within 4 weeks before enrollment; 4. there can not be controlled by drainage or pneumatic methods third space effusion; 5. patients with other malignant tumors within the past 3 years, excluding radical cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma; 6. suffering from serious or uncontrolled diseases, including but not limited to: 1) active viral infection, such as HIV or HBV active (HbsAg positive and HBV-DNA≥103, hepatitis C antibody positive); 2) history of severe cardiovascular disease: uncontrolled hypertension; Myocardial infarction, unstable arrhythmia, congestive heart failure, pericarditis, myocarditis, etc. Patients with NYHA class ⅲ-ⅳ cardiac dysfunction, or left ventricular ejection fraction (LVEF) 50% by echocardiography; 3) severe infection (e.g., intravenous antibiotic, antifungal, or antiviral therapy according to clinical practice) within 4 weeks prior to the first dose or unexplained fever during screening/before the first dose; 38.3°C (fever due to cancer, as judged by the investigator, was eligible); 7. patients with a history of psychotropic drug abuse and unable to abstain or with mental disorders; Or accompanied by swallowing and absorption dysfunction; 8. patients with other concomitant diseases that seriously endanger the safety of patients or affect the completion of the study according to the judgment of the investigators; 9. patients with known history of allergy to the components of this regimen; A history of immunodeficiency, including testing positive for HIV, HCV or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation; 10. pregnant or lactating women; 11. Patients deemed unsuitable for inclusion by the investigators.

Optimize Pediatric OCT Imaging

NCT06139523
Recruiting
Conditions Retinal Disease, Glaucoma, Optic Nerve D...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina. The investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Investigational contact OCT system — Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
  • Device: Investigational noncontact OCT system: — The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by: * Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt) * The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety.

Primary Outcomes

  • Presence of abnormal retinal microanatomy as measured by OCT reading (Single imaging session (day 1))
  • Severity of abnormal retinal microanatomy as measured by OCT reading (Single imaging session (day 1))
  • Retinal thickness at the fovea and surrounding optic nerve as measured by OCT analysis (Single imaging session (day 1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-24
Completion: 2027-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Contact Information
Study Contact:
Xi Chen, MD
(919)684-8434
xi2.chen@duke.edu
Michelle N McCall, MCAPM, BA
(919) 684-0544
michelle.mccall@duke.edu
Michelle McCall
919-684-0544
mccal023@mc.duke.edu
Duke University Eye Center
Interventions
  • Device: Investigational contact OCT system — Theia imaging is developing handheld OCT systems bring state of the art OCT to the infant bedside. The Theia 1 widefield imaging system is a light weight, high speed (300 kHz), wide field of view (110°) OCT system that address the limitations of current commercial OCT systems. The system is cart mounted, enabling portable, bedside imaging. The system uses a 300 kHz swept source laser operating in 1060nm regime. The Theia system follows the same safety standards as all applicable laser safety standards (ANSI z80.36 or ISO 15004) as the currently approved prior OCT devices. This nearly 10-fold increase in acquisition speed dramatically reduces imaging time and enables acquisition of full retinal volumes in infants. The 110° field of view is provided via a re-usable contact lens that can be sterilized between imaging sessions.
  • Device: Investigational noncontact OCT system: — The investigational noncontact handheld OCT systems in this study is developed at Duke University as the result of collaboration between the Departments of Ophthalmology (Cynthia Toth, MD) and Biomedical Engineering (Joseph Izatt, PhD). This investigational device was previously reviewed and approved for use in adults, children, and neonates in nursery by: * Intraoperative OCT Guidance of Intraocular Surgery study's (Pro00016827) Data Safety and Monitoring Board Plus (DSMB+) (PI: Toth and Izatt) * The Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care study (Pro00069721) Data Safety and Monitoring Committee (DSMC) (PI: Toth) The systems were declared non-significant risk by the Duke University Health System (DUHS) Institutional Review Board under Pro00016827. Staff from the DUHS Clinical Engineering Department evaluated the systems and found that they meet the accepted hospital standards for electrical safety.
Study Locations (1 sites)
Duke University Eye Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: * Group 1 - Healthy adult volunteers * Subject is able and willing to consent to study participation * Subject is more than 18 years of age * Healthy adult volunteers without known ocular issues other than refractive error * Pregnancy Reasonably Excluded Guide (PREG) evaluation on women of childbearing potential * Group 2 - Pediatric participants * Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent/legal guardian * Parent/legal guardian is able and willing to consent to study participation * Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center Exclusion Criteria: * Group 1 - Healthy adult volunteers * Students or employees under direct supervision of the investigators * Subjects with prior problems with pupil dilation * Pregnant woman if receiving dilating drops * Group 2 - Pediatric participants * Parent/legal guardian unwilling or unable to provide consent * Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)
Conditions High Cholesterol, Diabetes, Obesity, Hyp...
Phase Not Applicable
Enrollment 8
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project will use a mixed design and will be conducted at the West Parry Sound Health Centre. Based on similar studies there is an expected 10% drop-out rate so 20 participants per group will be invited to aim to have 15 finish. Total participants invited over the two-year study will be 40. The participants will be followed over a Complete 6-month Lifestyle medicine Intervention Program (CLIP) involving a collaboration between physicians, health coach, registered dietitians, and kinesiology. The CLIP will cover the 6 pillars of lifestyle medicine in 12-14 fundamentals of lifestyle medicine group classes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Lifestyle Medicine — Education and support for lifestyle modification to improve health conditions

Primary Outcomes

  • Participant Feedback (1 month)
  • Participant Feedback (1 month)
  • Participant Feedback (1 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-06
Completion: 2026-11-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 8 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northern Ontario School of Medicine
Principal Investigators:
  • Caroline Rheaume, MD (STUDY_CHAIR) - Laval
Contact Information
Study Contact:
Lisa Allen, PhD
7056622901
lisa.allen@mahc.ca
Mylene Juneau, MN
705-746-9321
mylene@whole-health.ca
West Parry Sound Health Centre
Mylene Juneau, MD
West Parry Sound Health Centre
Interventions
  • Behavioral: Lifestyle Medicine — Education and support for lifestyle modification to improve health conditions
Study Locations (1 sites)
West Parry Sound Health Centre, Parry Sound, Ontario P2A3A4 Canada
Eligibility Criteria
Inclusion Criteria: * prediabetes, * type 2 diabetes, * pre-hypertension, * systemic hypertension, * heart disease, dyslipidemia, * and/or excess weight (BMI ≥ 25 (42)). Exclusion Criteria: * Healthy participants
Conditions Depressive Symptoms
Phase NA
Enrollment 236
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression is a major public health concern. In Dutch adolescents, the prevalence of major depressive disorder is estimated at 3.8%, and one in five adolescents report depressive symptoms. Depression is a risk factor in adolescent suicide. School-based prevention programs, for example the STORM approach, are effective in decreasing depressive symptoms among adolescents with elevated depressive symptoms at screening. However, not all adolescents attend general education. In the Netherlands, 7% of all adolescents enters special education (voortgezet speciaal onderwijs and prakijkonderwijs). They form a vulnerable subgroup concerning developing depressive symptoms and suicidality. To adapt and implement programs for these students, is complex yet crucial. This study aims to screen adolescents, offer them a prevention program to prevent the onset or continuation of depression and evaluate the effectiveness of this program. It is a randomised controlled trial with two conditions. The main study parameter is depressive symptomatology. Secondary study parameters are suicidality, anxiety and somatic complaints. Eligible students enter the second or third grade of special education, presenting elevated depressive symptoms. All adolescents will be screened for depressive and suicidal symptoms. Those reporting suicidality will be guided to specialised care, together with their parents. Adolescents with elevated depressive symptoms in the experimental condition will be offered the CBT-based preventive group training Op Volle Kracht in their school setting. The control condition consists of monitoring, and is offered the training if the intervention has shown to be effective. Participants will fill in longitudinal measurements. At all times, adolescents will be guided to mental health care if necessary. Furthermore, teachers in all participating schools will attend a training on how to detect and address depressive and suicidal symptoms among adolescents. The potential value of the study is that we can offer adolescents in the special educational sector a prevention program that is proven to be effective. In order to achieve this goal we need to evaluate the effectiveness of this prevention program in this target group. We are of opinion, however, that the risks associated with participation can be considered negligible. It is specifically aimed at depressive symptoms, within a population which receives care for other problems.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Op Volle Kracht — This is a preventive group training based on cognitive behavioural therapy for depression.
  • Behavioral: Gatekeeperstraining — This is a training for teachers to detect and address depressive symptoms and suicidality in their students .

Primary Outcomes

  • Depressive symptoms in children and adolescents (Depressive symptoms will be measured at the screening, at T0 (baseline), T1 (12 weeks), T2 (6 months), and T3 (12 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-13
Completion: 2027-08-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 236 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ggz Oost Brabant
Principal Investigators:
  • Wendy CH Rongen, MSc (PRINCIPAL_INVESTIGATOR) - Ggz Oost Brabant
Contact Information
Study Contact:
Wendy CH Rongen, MSc
+31888461968
WCH.Rongen@ggzoostbrabant.nl
Wendy WC Rongen, MSc
+31888461968
wch.rongen@ggzoostbrabant.nl
GGZ Oost Brabant
Interventions
  • Behavioral: Op Volle Kracht — This is a preventive group training based on cognitive behavioural therapy for depression.
  • Behavioral: Gatekeeperstraining — This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
Study Locations (1 sites)
GGZ Oost Brabant, Boekel, Noordoost Brabant 5427 ZG Netherlands
Eligibility Criteria
Inclusion Criteria: * Adolescents are in their second or third year of secondary education, ór adolescents will reach the age 14 or 15 in this academic year. * Score above cut-off on depression symptom questionnaire (≥ 14 on the CDI-2; Bodden et al. (2016)). Exclusion Criteria: * Adolescents who score 2 on item 8 of the CDI-2 or ≥ 23 on the VOZZ-screen (Kerkhof et al., 2015). * Clinical depression based on the clinical interview at baseline ADIS-C (Silverman \& Albano, 1996). * Absence of parental permission. * Adolescent already receiving treatment for depressive symptomatology. * Insufficient knowledge of the Dutch language.
Conditions Depression
Phase NA
Enrollment 152
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depressive symptoms are common among Veterans and associated with significant impairment. Timely intervention has the potential to improve mental health outcomes and restore functioning. Interventions delivered through the internet can be completed remotely at any time, and thus minimize burden on Veterans, however the research examining their utility in Veterans is limited. This proposed project will examine Deprexis, a self-guided internet-delivered intervention, which targets depressive symptoms and associated functional impairments. Interviews will be conducted to gain insight into Veterans' perceptions, needs, and preferences vis-a-vis Deprexis, with results informing a randomized controlled trial. Here an 8-week course of Deprexis will be compared to a treatment-as-usual (TAU) control condition to establish if Deprexis is acceptable and effective for Veterans with mild to moderate depressive symptoms. Veterans engaged in Deprexis are hypothesized to show improvements on measures of functioning and decreases in depressive symptoms compared to the TAU control group. The proposed work has great clinical utility, as it could provide a readily accessible, high-quality intervention for the many Veterans suffering from depressive symptoms, with the potential to improve functioning and long-term outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Deprexis — Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.

Primary Outcomes

  • Quick Inventory of Depressive Symptomatology (Self-Report; QIDS-SR-16) Change (Baseline, Post-Treatment (week 8), Follow-up (week 16))
  • World Health Organization Disability Assessment Schedule-II (WHODAS) Change (Baseline, Post-Treatment (week 8), Follow-up (week 16))
  • The Sheehan Disability Scale (SDS) Change (Baseline, Post-Treatment (week 8), Follow-up (week 16))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-01
Completion: 2029-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 152 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Rahel R Pearson, PhD (PRINCIPAL_INVESTIGATOR) - Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
Contact Information
Study Contact:
Rahel R Pearson, PhD
(254) 297-5155
rahel.pearson@va.gov
Suzannah K Creech, PhD
(254) 297-3025
Suzannah.Creech@va.gov
Rakesh Guleria
(254) 297-3291
rakeshwar.guleria@va.gov
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
Interventions
  • Behavioral: Deprexis — Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
Study Locations (1 sites)
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX, Waco, Texas 76711 United States
Eligibility Criteria
Inclusion Criteria: Potential participants include male and female Veterans of all races/ethnicities who are: * able to comprehend and sign the informed consent form * have reliable access to the internet and a computer, tablet and/or smartphone * exhibit mild or moderate, but not very severe, levels of depression * stable on psychotropic medications Exclusion Criteria: Aim 1 and Aim 2: Veterans will be excluded from study participation if they: * endorse any positive symptoms of a psychotic disorder * screen positive for Bipolar I Disorder * report current suicidal risk
Conditions Fludzoparib&#34; and Anti-angiogenic, HR...
Phase PHASE3
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study develops a new therapeutic approach for HER2-negative advanced breast cancer patients without precise treatment targets. The trial aims at extending the combination target therapy involving PARP inhibitors and anti-angiogenesis from only BRCA mutation carriers to all patients with homologous recombination repair defects (HRD-positive). The phase III randomized clinical study will investigate the effectiveness of the combination therapy of PARP inhibitor "fludzoparib" and anti-angiogenic "apatinib" in treating HRD-positive/HER2-negative advanced breast cancers.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fluzoparib — Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Apatinib Mesylate — Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
  • Drug: Capecitabine tablets — Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Vinorelbine Tartrate Oral — For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
  • Drug: Eribulin mesylate injection — Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Gemcitabine Hydrochloride — Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Paclitaxel-albumin — Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).

Primary Outcomes

  • Progression Free Survival,PFS(Independent Review Committee) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-06-12
Completion: 2031-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Jianli Zhao (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Zhao Jianli
86-20-34070870
zhaojli5@mail.sysu.edu.cn
Jianli Zhao
020-34070870
zhaojli5@mail.sysu.edu.cn
Sun Yat Sen Memorial Hospital,Sun Yat sen University
Ying Wang
020-34070499
wangy556@mail.sysu.edu.cn
Sun Yat Sen Memorial Hospital,Sun Yat sen University
Interventions
  • Drug: Fluzoparib — Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Apatinib Mesylate — Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
  • Drug: Capecitabine tablets — Capecitabine tablets, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
  • Drug: Vinorelbine Tartrate Oral — For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
  • Drug: Eribulin mesylate injection — Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study Locations (1 sites)
Sun Yat Sen Memorial Hospital,Sun Yat sen University, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion criteria The subjects must meet all of the following conditions: Adult female patients (aged 18 to 70 years) with metastatic breast cancer diagnosed by pathology or imaging; 2) Pathological confirmation of HER2 negative (definition: immunohistochemical result is 0 or + or ++ and in situ hybridization result is negative); 3) The patient's HRD test was positive (definition: BRCA1/2 mutation, or HRD score greater than or equal to 42 points); 4) HR+/HER2- patients who have received endocrine therapy during the metastasis stage; 5) Having received no more than two lines of chemotherapy (or ADC) regimens for metastatic breast cancer in the past; 6) Evaluation of anti-tumor treatment (including chemotherapy /HER2-ADC/TROP2-ADC) for 6-8 cycles to achieve clinical benefit (CR or PR) or SD for 24 weeks or more; 7) ECOG physical condition score ≤2 points, and the expected survival period is no less than 3 months; 8) At least one measurable lesion was found in the imaging examination within 2 weeks before enrollment. Or simple bone metastasis lesion; 9) At the time of enrollment, the previous treatment-related toxicity must be remitted to NCI CTCAE (Version 5.0) ≤1 degree (except for alopecia or other toxicities that the investigator deems to pose no risk to the patient's safety). 10\) Adequate bone marrow functional reserve: 1. White blood cell count (WBC) ≥3.0×10\^9 / L 2. Neutrophil count (ANC) ≥1.5×10\^9 / L 3. Platelet count (PLT) ≥70×10\^9 / L 11) Liver, kidney and heart function tests are basically normal (based on the normal values in the laboratories of each research center) : a. Total bilirubin (TBIL) ≤3× upper limit of normal (ULN) b. Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (≤5 ×ULN for patients with liver metastasis) c. Serum creatinine ≤1.5×ULN or creatinine clearance rate (Ccr) ≥60 ml/min; d.Left ventricular ejection fraction (LVEF) ≥ 55%, e. QTcF(Fridericia correction) ≤ 470 ms. 12) Be able to understand the research process, voluntarily participate in this research, and sign the informed consent form. Exclusion Criteria If a subject experiences any of the following situations, they will not be eligible to participate in this study: 1. Patients with HR+/ HER2-MBC who have not received endocrine therapy before; 2. Has not received any treatment for metastatic breast cancer; 3. Received more than two chemotherapy regimens for metastatic breast cancer; 4. Patients who are known to be allergic to the active ingredient or other ingredients of the investigational drug. 5. Pregnant or lactating women, and women of childbearing age who refused to take effective contraceptive measures during the study period. 6. Those with severe heart disease or discomfort, expected to be unable to tolerate chemotherapy, including but not limited to: fatal arrhythmia or higher-grade atrioventricular block, unstable angina pectoris, clinically significant valvular heart disease, electrocardiogram showing transmural myocardial infarction, uncontrollable hypertension; 7. Any other circumstances where the researcher deems the patient unsuitable for participation in this study, any concomitant diseases or conditions that may interfere with participation in the study, or any serious medical conditions that may affect the safety of the subjects (such as uncontrollable heart disease, hypertension, active or uncontrollable infection, active hepatitis B virus infection).
Conditions Chronic Kidney Disease, Type 2 Diabetes ...
Phase Not Applicable
Enrollment 50000
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational study, in which data from people in Asia and in the United States with chronic kidney disease (CKD) together with type 2 diabetes (T2D) are studied. The participants in this study are already receiving the study treatment finerenone as part of their regular care from their doctors. In observational studies, only observations are made without specified advice or interventions. CKD is a long-term progressive decrease in the kidneys' ability to work properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough. The resulting high blood sugar levels can cause damage to the kidneys. CKD often occurs together with T2D or as a consequence of T2D. Finerenone works by blocking certain proteins, called mineralocorticoid receptors. By doing this, it may reduce damage to kidneys, heart and blood vessels. Finerenone was recently approved in the US and is now available for doctors to prescribe to people with CKD together with T2D. Consequently, there is a need to collect more information about how finerenone is used, its safety and how well it works under real-world conditions. The main purpose of this study is to collect and describe the characteristics of people with CKD and T2D who are receiving initiate finerenone treatment as prescribed by their doctors. To do this, the researchers will collect general information of the participants such as age or gender and data on kidney function and possible heart problems. The researchers will also collect data on any other disease or medical condition in the participants and on other medications used while taking finerenone. The data will come from a network of commercial electronic health records (EHRs) and national claims data in the United States and in Asia. They cover the period from July 1st, 2021 until the latest data cut available for each dataset. Only already available data is collected and studied. There are no required visits or tests in this study.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Finerenone (BAY 94-8862) — 10 mg or 20 mg daily

Primary Outcomes

  • Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone. (12 months before first prescription/dispensation of finerenone (index date))
  • Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone. (12 months before first prescription/dispensation of finerenone (index date))
  • Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone. (12 months before first prescription/dispensation of finerenone (index date))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-05-15
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bayer
Contact Information
Study Contact:
Bayer Clinical Trials Contact
(+)1-888-84 22937
clinical-trials-contact@bayer.com
Interventions
  • Drug: Finerenone (BAY 94-8862) — 10 mg or 20 mg daily
Study Locations (4 sites)
Many Locations, Multiple Locations, New Jersey 07981 United States
Bayer, Berlin, 13353 Germany
Many Locations, Multiple Locations, Japan
Many Locations, Multiple Locations, Taiwan
Eligibility Criteria
Inclusion Criteria: * A minimum of 12 months of continuous enrolment in the databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR or claims system, depending on the database used * No recorded prescription for finerenone in the 12 months prior to the index date * Age of 18 years or older as of the index date * Evidence of T2D at any point before (and including) the index date. * CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date: * A diagnosis code indicating CKD stage 2, 3, 4 or stage unspecified * two UACR tests results ≥ 30 mg/g separated by at least 90 days and by not more than 540 days * two different eGFR test results ≥ 15 mL/min/1.73 m2 AND \< 60 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days Exclusion Criteria: \- Kidney failure defined as follows: * Two different eGFR test results \< 15 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days; * Dependence on dialysis (at least 3 sessions over at least 90 days during the baseline period); * A diagnosis code indicating kidney failure or CKD stage 5; Kidney transplant
Conditions Depression, Depressive Disorder, Major, ...
Phase NA
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this triple-blind randomized controlled trial, we ask if targeting intermittent theta burst stimulation (iTBS) based on individual resting state connectivity improves treatment outcomes in major depressive disorder (MDD). For the trial, we will recruit 210 patients with major depressive disorder. Each patient will undergo a 30-40-minute MRI scan, after which they will receive a 6-week standard iTBS treatment. Participants will be randomized to receive iTBS either to the standard neuronavigated target (a technique for treatment location targeting, based on group-average connectivity) or to a personalized connectivity-guided target selected based on individual functional connectivity scans. The main outcome of this trial is response rate as determined by ≥ 50% reduction in Grid HRSD-17 scores. Secondary outcomes include remission rate, change in depression, anxiety and anhedonia symptoms, quality of life, and biological measures of heart rate variability, objective sleep measures and daily activity as a proxy of anhedonia - defined as a reduced ability to experience pleasure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: repetitive Transcranial Magnetic Stimulation — Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).

Primary Outcomes

  • Compare the efficacy of fMRI guided TMS and conventional neuronavigated TMS on clinical response. (Administered at baseline (prior to first iTBS treatment) and every 2 weeks after that for 6 weeks (week 2, week 4, and week 6).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-16
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal Ottawa Mental Health Centre
Principal Investigators:
  • Sara Tremblay, PhD (PRINCIPAL_INVESTIGATOR) - The Royal&#39;s Institute of Mental Health Research
  • Lauri Tuominen, MD PhD (PRINCIPAL_INVESTIGATOR) - The Royal&#39;s Institute of Mental Health Research
Contact Information
Study Contact:
Stacey Shim, MSc
613-722-6521
stacey.shim@theroyal.ca
Emma Cummings, BA
613-722-6521
emma.cummings@theroyal.ca
Sara Tremblay, PhD
6137226521
Sara.Tremblay@theroyal.ca
The Royal's Institute of Mental Health Research
Interventions
  • Device: repetitive Transcranial Magnetic Stimulation — Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
Study Locations (1 sites)
The Royal's Institute of Mental Health Research, Ottawa, Ontario K1Z 7K4 Canada
Eligibility Criteria
Inclusion criteria: For inclusion in the study, participants must fulfill all the following criteria: 1. voluntary and competent to consent to study, 2. Adults aged 18 years old or older, 3. can speak and read English, 4. primary and/or predominant diagnosis of major depressive episode without psychotic features in the current episode (confirmed by a Mini-International Neuropsychiatric Interview), 5. depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant trial in the current depressive episode, 6. moderate symptoms in the current depressive episode as indexed by a score of at least 15 on the Grid 17-item Hamilton Rating Scale for Depression (Grid HRSD-17), 7. have been referred to rTMS treatment by their treating physician, and took a free and informed decision to follow this treatment, 8. are able to adhere to treatment schedule, 9. have stable psychotropic medications (including prescribed cannabis) or psychotherapy regimen for at least four weeks prior to entering the trial, 10. have an education-adjusted score of ≥ 24 at the Mini-Mental State Evaluation (MMSE) if they are aged ≥ 65. Exclusion criteria: Participants fulfilling any of the following criteria will be excluded from the study: 1. diagnosis of bipolar I or II disorder, based on the DSM-5 criteria 2. current or past (\< 3 months) substance (excluding caffeine or nicotine) or alcohol use disorder, as defined in DSM-5 criteria. Based on the DSM-5 criteria, mild cannabis or alcohol use disorder would be permissible in the past 3 months, moderate to severe would be an exclusion. 3. current use of illegal substances or cannabis (unless medical use, see note below), confirmed by urine drug screen 4. have a concomitant major unstable medical or neurologic illness (e.g. uncontrolled diabetes or renal dysfunction), 5. organic cause to the depressive symptoms (e.g. thyroid dysfunctions), as ruled out by the referring physician 6. acute suicidality or threat to life from self-neglect, 7. are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment (pregnancy will be assessed by a urine test), 8. have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker), 9. unwilling to maintain current antidepressant regimen, 10. are taking more than 1 mg of lorazepam per day or equivalent, 11. any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study, 12. any contraindications for MRI 13. have failed a course of ECT within the current depressive episode due to the lower likelihood of response to rTMS (if they have had failed ECT in the past, this does not exclude them)
Conditions HER2-positive Metastatic Breast Cancer, ...
Phase PHASE3
Enrollment 312
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this multicentre, randomized, double-blind controlled, phase III clinical trial is to compare the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of paclitaxel in combination with trastuzumab and pertuzumab (THP) for newly diagnosed recurrent/metastatic Human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer, and to explore the impact of biomarkers on clinical efficacy and safety. The main questions it aims to answer are: * Analyse the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of THP. * Explore the impact of biomarkers on clinical efficacy and safety of the combination of disitamab vedotin in combination with pyrotinib treatment. Participants in the experimental group will receive disitamab vedotin in combination with pyrotinib for 6-8 cycles (each cycle lasting 28 days), followed by maintenance treatment with trastuzumab in combination with pyrotinib. Participants in the control group will receive paclitaxel in combination with trastuzumab and pertuzumab for 6-8 cycles (each cycle lasting 21 days), followed by maintenance treatment with trastuzumab and pertuzumab. Researchers will compare disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of paclitaxel in combination with trastuzumab and pertuzumab to see if disitamab vedotin in combination with pyrotinib could be a new option for first-line treatment of HER2-positive metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: disitamab vedotin — disitamab vedotin 2mg/kg iv q2w
  • Drug: Pyrotinib — pyrotinib 400mg po q28d
  • Drug: trastuzumab — trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
  • Drug: Pertuzumab — pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
  • Drug: taxane drug — Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations

Primary Outcomes

  • Progression Free Survival (PFS) (Estimated 30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-09-06
Completion: 2031-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 312 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Herui Yao, PhD
+86 13500018020
yaoherui@mail.sysu.edu.cn
Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Interventions
  • Drug: disitamab vedotin — disitamab vedotin 2mg/kg iv q2w
  • Drug: Pyrotinib — pyrotinib 400mg po q28d
  • Drug: trastuzumab — trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
  • Drug: Pertuzumab — pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
  • Drug: taxane drug — Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: 1. Adult female patients (age 18-75 years) with metastatic breast cancer confirmed by pathology or imaging; 2. Pathologically confirmed HER2 positive (definition: Immunohistochemistry(IHC) 3+, or IHC 2+ and Fluorescent In Situ Hybridization(FISH) amplification); 3. No previous chemotherapy regimen for metastatic breast cancer; 4. At least one measurable lesion exists (Response Evaluation Criteria in Solid Tumors(RECIST) 1.1); 5. Eastern Cooperative Oncology Group(ECOG) performance status score ≤ 2 and expected survival of not less than 3 months; 6. Prior treatment-related toxicity at enrollment must have resolved to National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE) (version 5.0) ≤ 1 degree (except for alopecia or other toxicity that, in the judgment of the investigator, is not considered a risk to the safety of the patient); 7. Patients with adequate organ function before enrollment: 1. White Blood Cell (WBC) ≥ 3.0 x 10\^9/L; 2. Neutrophil granulocyte (ANC) ≥1.5 x 10\^9/L; 3. Platelet (PLT) ≥70×10\^9/L; 8. Liver, kidney, and cardiac function tests are essentially normal (based on the normal values in the laboratory of each study center): 1. Total bilirubin (TBIL) ≤ 3 x Upper Limit of Normal (ULN); 2. Alanine aminotransferase (ALT/AST) ≤ 2.5 x ULN (≤ 5 x ULN in patients with liver metastases); 3. serum creatinine ≤ 1.5 x ULN or creatinine clearance (Ccr) ≥ 60 ml/min; 9. . Normal cardiac function; 1. Left ventricular ejection fraction (LVEF) ≥ 55%; 2. QT-interval corrected with Fridericia (QTcF) ≤ 470ms; 10. Hormone receptor status is clear; 11. Female patients of childbearing potential who have a negative pregnancy test and agree to use an effective non-hormonal method of contraception during treatment and for at least 6 months after the last dose of the test drug; 12. Able to understand the study process, voluntarily participate in this study, and sign an informed consent form. Exclusion Criteria: 1. Pathology suggestive of HER2 negativity (IHC 2+ and FISH-, or IHC 1+); 2. Patients with known hypersensitivity to the active ingredient or other components of the study drug; 3. Patients during pregnancy or lactation, patients with childbearing potential tested positive in a baseline pregnancy test, or patients unwilling to take effective contraceptive measures throughout the trial; 4. Patients not eligible for this study judged by the investigator, a pre-existing disease or condition that may interfere with participation in the study or any serious medical disorder that may interfere with the safety of the subject (e.g., uncontrolled heart disease, high blood pressure, active or uncontrolled infections, active hepatitis B virus infection).
Conditions Autism, Autism Spectrum Disorder, Autism...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In addition to the "core" symptoms of ASD (i.e., impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests), it is estimated that up to 70% of autistic people present at least one comorbid psychiatric disorder, leading to a deterioration in quality of life, a greater demand for support and worse prognosis and outcome. Anxiety and depressive symptoms would seem to be more present in individuals with Level 1 ASD, requiring their prioritisation against core symptoms. To date, the first-line treatment for autistic patients with comorbid depressive and/or anxiety symptoms is still debated and it is not always clear whether they may or may not benefit from psychotherapeutic and conventional psychopharmacological approaches. As such, growing evidence strengthens the therapeutic potential of the endocannabinoid (eCB) system modulation and of eCB-like compounds. The aim of this study is to provide a response to an unmet clinical need in this framework of psychic vulnerability by initiating oral therapy with palmitoylethanolamide (PEA), a nutraceutical/food supplement with proven anti-inflammatory and neuroprotective properties. Indeed, many conditions of psychological distress are thought to be underpinned by systemic inflammatory and/or neuroinflammatory processes, on which PEA has shown remarkable efficacy, including through modulation of the immune response and the interaction between the endocannabinoid system and the gut-microbiota-brain axis. The trial we are proposing is a 12-week open-label phase 2 study involving the daily intake of PEA 600 mg, at a dosage of 1 tablet/day. This study will be conducted at the Unit of Psychiatry of Santa Maria della Misericordia Udine University Hospital. Through this study, we wish to evaluate: the ability of PEA to alleviate symptoms of psychic distress (i.e., anxiety and/or depression) in Level 1 autistic adults; the safety and tolerability of sustained intake of PEA in Level 1 autistic adults; and the biological basis of PEA functioning. The study involves taking PEA orally once daily (600 mg daily) at the same time as a meal during the initial 12-week phase. Upon completion of the initial phase, subjects will be offered to enter an extension phase of the trial of an additional 24 weeks to assess treatment stability, with the possibility of titration of PEA to 1200 mg daily based on observed clinical compensation. Each participant will be on PEA treatment for up to 36 weeks. During the course of the study, periodic clinical re-evaluations will be conducted at our Day-Hospital setting. The trial will unfold through one screening visit, one baseline visit, and two follow-up visits (FUP, 4 weeks and 12 weeks apart). The patient will be administered standardized interviews by a qualified investigating physician; clinical objective examination, collection of blood and urine samples for standard hematochemical investigations…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form — Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.

Primary Outcomes

  • Symptom-Checklist-90-R (12 weeks for the initial phase, further 24 weeks for the extension phase)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2026-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Udine
Principal Investigators:
  • Marco Colizzi, MD, PhD (PRINCIPAL_INVESTIGATOR) - Unit of Psychiatry, Department of Medicine (DAME), University of Udine (UNIUD)
Contact Information
Study Contact:
Marco Colizzi, MD, PhD
+390432559155
marco.colizzi@uniud.it
Riccardo Bortoletto, MD
+393484739255
bortoletto.riccardo@spes.uniud.it
Marco Colizzi, MD, PhD
+390432559155
marco.colizzi@uniud.it
Unit of Psychiatry, University Hospital of Udine
Interventions
  • Dietary Supplement: Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form — Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
Study Locations (1 sites)
Unit of Psychiatry, University Hospital of Udine, Udine, UD 33100 Italy
Eligibility Criteria
Inclusion Criteria: * Individuals diagnosed with Level 1 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5); * Aged 18-35 years; * To be able to understand and communicate in Italian; * To be able to give informed consent. Exclusion Criteria: * Level 2 or Level 3 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) \[47\]; * Current diagnosis of a co-occurring major psychiatric disorder (e.g., major depressive disorder, bipolar affective disorder, psychotic disorders); * Active suicidal ideation indicating significant current risk or history of serious suicide attempt in the opinion of the PI, as evaluated at the screening stage; * Lifetime neurological disorders (e.g., epilepsy, except febrile convulsions) or severe intercurrent physical illness; * Current treatment with psychotropic medication, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) stable monotherapy (at least 8 months); * IQ \< 70; * Female patients who are pregnant, lactating or not using an acceptable effective form contraception if they are at risk of falling pregnant; * Taking part in another pharmacological trial.
Conditions Breast Cancer
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-center, phase 1b study evaluating the safety and feasibility of a neoadjuvant treatment with tucatinib, trastuzumab and pertuzumab in stage II-IIIA HER2-positive breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tucatinib — Tucatinib 300mg is taken orally twice daily
  • Drug: Trastuzumab — Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
  • Drug: Pertuzumab — Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle

Primary Outcomes

  • Incidence and severity of adverse events (an average of 8 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-12-18
Completion: 2036-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: Seagen Inc.
Contact Information
Study Contact:
Gabe Sonke, MD PhD
+31205129111
trainstudies@nki.nl
Netherlands Cancer Institute
Interventions
  • Drug: Tucatinib — Tucatinib 300mg is taken orally twice daily
  • Drug: Trastuzumab — Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
  • Drug: Pertuzumab — Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
Study Locations (1 sites)
Netherlands Cancer Institute, Amsterdam, 1066CX Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent 2. Histologically confirmed primary invasive breast cancer 3. Stage II - IIIA primary breast cancer according to TNM-staging (8th edition, AJCC); (largest tumor diameter on DCE-MRI ≥ 2cm (cT2-3) and/or cN1-2 confirmed with FNA or histology) 4. HER2 overexpression defined as circumferential membrane staining that is complete, intense and in \>10% of invasive tumor cells (IHC 3+) on pre-treatment biopsy 5. Known estrogen- and progesterone-receptor expression of the invasive tumor a. ER-negative or PR-negative is defined as \<10% of invasive tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER and/or PR 6. WHO performance status 0-1 7. Age ≥ 18 years 8. LVEF ≥50% measured by echocardiography or MUGA 9. Eligible for neoadjuvant treatment 10. Laboratory requirements within 21 days prior to enrollment: 1. Adequate bone marrow function (ANC ≥1.5 x 109/l, platelets ≥100 x 109/l); 2. Adequate hepatic function (ALAT, ASAT and bilirubin ≤2.5 times upper limit of normal). Subjects with Gilbert's syndrome may have a total bilirubin ≥2.5 × the ULN range, if no evidence of biliary obstruction exists. 3. Adequate renal function: creatinine clearance \>50 ml/min estimated using the Cockcroft-Gault equation or MDRD equation, or based on a 24-hour urine collection measurement. Exclusion Criteria: 1. Current pregnancy or breastfeeding 2. Current or previous other malignancy unless treated without systemic therapy and more than five years ago 3. Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule 4. Use of a strong CYP3A4 or CYP2C8 inhibitor within five half-lives of the inhibitor, or used a strong CYP3A4 or CYP2C8 inducer within five days prior to first dose of study treatment 5. Known chronic liver disease 6. History of inflammatory bowel disease or bowel resection 7. Contraindications for MRI 8. Inflammatory breast cancer, cT4 and/or cN3 tumors 9. Occult breast cancer (cT0)